CS Diagnostics Corp.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CS Diagnostics Corp. provides innovative diagnostic and protective solutions for the healthcare, hospitality, and education sectors, delivering advanced medical and safety products with global reach. Headquartered in Cheyenne, Wyoming, the company operates across the United States, Europe, and the Middle East/North Africa (MENA) regions, leveraging strategic partnerships and ongoing product development to expand market penetration and capabilities. Main Products and Services: CS Diagnostics Corp. focuses on diagnostic and protective medical devices and related consumables, including proprietary imaging and contrast-enhancing technologies for MRI and CT applications; high-pressure syringe systems and tubing for diagnostic workflows; and protective solutions designed to improve hygiene, safety, and efficiency in clinical and non-clinical environments. The company divides its portfolio into core product categories such as CS Diagnostics PHARMA tubing systems; ZENITH series syringe injectors (C-22, C-60) for MRI/CT contexts; CSProtect hydro-based protective solutions; and related consumables, adapters, and accessories tailored for radiology and interventional procedures. It also emphasizes ongoing R&D, regulatory-compliant manufacturing, and integration-ready hose and syringe systems compatible with popular imaging platforms such as Medrad Spectris Solaris and Medtron Accutron CT models. Latest Major Company Changes: CS Diagnostics Corp. announces accelerated global expansion through regulatory milestones and strategic alliances, reinforcing its international footprint and product approvals. The company pursues targeted partnerships to broaden distribution networks and access new markets, while pursuing capital infusions and disclosures that support scale-up of manufacturing, product launches, and service capabilities. Recent communications highlight ongoing enhancements to diagnostic services and protective product lines, including expansion into additional geographic regions and adoption of new licensing or IP strategies to monetize novel technologies. Industry context and business segments: The firm operates within the medical devices and healthcare diagnostic tools sector, with business lines spanning diagnostic imaging aids, protective solutions for clinical settings, and related accessories and consumables. Primary customer types include hospitals, radiology centers, clinics, and organizations requiring infection control and patient safety enhancements. Geographic operations cover the United States, Europe, and MENA regions, with potential subsidiaries or affiliates supporting regional sales, regulatory compliance, and service delivery. Founded in 2014 and headquartered in Cheyenne, Wyoming, CS Diagnostics maintains a structure that includes partnerships and potential parent/subsidiary relationships to support international growth and IP commercialization.
CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH
CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH
CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products
CS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene Products
CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP
CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP
CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering
CS Diagnostics Corp. (OTCQB: CSDX) Accelerates Global Expansion with Key Regulatory Milestones and Record Growth
CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market
CS Diagnostics Corp. Submitted Final Form-10 Registration Statement Draft to the processing team for preparation of Edgardization and filing with the U.S. Securities and Exchange Commission ("SEC")
CS Diagnostics Corp. to Present at the Small Cap Growth Virtual Investor Conference June 26th
CS Diagnostics Corp. CSDX to Present at the Small Cap Growth Virtual Investor Conference on June 26, 2025 at 12:30pm EDT
CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS
OTCQB-CSDX Appoints Lachman Consultants for CS-Protect Hydrogel FDA Approval